Physician profile
Daniel Parker
NPI 1457633588
$5,184.17
in general payments reported to CMS, 2019-2025
25 companies · $790 in 2025
The $790 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.11 · 2020: $157 · 2021: $2,763 · 2022: $331 · 2023: $120 · 2024: $961 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,134 · Travel and Lodging: $713 · Education: $23.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,134.35 |
| Travel and Lodging | $712.52 |
| Education | $23.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Photocure INC | $2,672.03 | 2020-2021 | |
| Valencia Technologies Corporation | $712.52 | 2024 | Ecoin Device Kit |
| Boston Scientific Corporation | $315.50 | 2019-2025 | Ams 700 |
| Novartis Pharmaceuticals Corporation | $225.19 | 2024-2025 | |
| Urogen Pharma, INC. | $189.76 | 2021-2025 | |
| Astellas Pharma US INC | $150.76 | 2019-2025 | Xtandi, Padcev |
| Medtronic, INC. | $138.51 | 2023-2025 | Interstim |
| Axonics, INC. | $114.59 | 2023-2024 | Axonics |
| Ferring Pharmaceuticals INC. | $85.59 | 2025 | Adstiladrin |
| Abbvie INC. | $69.75 | 2023-2024 | |
| Myovant Sciences INC. | $69.03 | 2022 | |
| Progenics Pharmaceuticals, INC. | $67.34 | 2023-2025 | Pylarify |
| Sumitomo Pharma America, INC. | $55.72 | 2024-2025 | Orgovyx |
| Antares Pharma, INC. | $47.69 | 2022 | |
| Merck Sharp & Dohme LLC | $47.41 | 2022-2024 | Keytruda |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $37.47 | 2025 | Posluma |
| Janssen Biotech, INC. | $32.44 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $32.10 | 2025 | |
| Verity Pharmaceuticals INC. | $24.58 | 2024 | Trelstar |
| Accord Healthcare, INC. | $18.34 | 2025 | |
| Urovant Sciences INC | $17.81 | 2022 | |
| Myriad Genetic Laboratories, INC. | $17.52 | 2025 | Prolaris |
| Endo USA, INC. | $17.10 | 2025 | Xiaflex |
| Ethicon US, LLC | $13.89 | 2025 | Echelon Flex |
| Laborie Medical Technologies Corp. | $11.53 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.